One‐year treatment outcomes of ziv‐aflibercept for treatment‐naïve macular oedema in branch retinal vein occlusion

Chan, Errol W.; Eldeeb, Mohab; Dedhia, Chintan; Mansour, Ahmad M.; Chhablani, Jay

doi:10.1111/aos.13432

Cited by 8 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown good visual and anatomical outcomes in ME associated with BRVO with both IVB and IVZ. [4891112] However, there are no studies comparing IVB and IVZ in BRVO-related ME. Ehlers et al .…”

Section: Discussionmentioning

confidence: 99%

“…In the 11 eyes treated through 12 months, best corrected visual acuity (BCVA) improved significantly (0.33 ± 0.22; P < 0.05) with 3.3 ± 1.6 mean number of injections on PRN protocol. [1216] Paulose et al . in a small series of nine eyes of persistent or recurrent ME because of RVO (both branch and central) reported modest improvement in BCVA (Δ = −0.29 logMAR; P = 0.13) with a significant reduction in CMT (604 ± 199 μm to 351 ± 205 μm; P = 0.02) at 4 months.…”

Section: Discussionmentioning

confidence: 99%

“…Mean number of injections were relatively less in both groups and the results bear a resemblance to other real-life studies on anti-VEGF therapy in ME secondary to BRVO. [4912] Moreover, this study has been done in two different populations. Therefore, the ethnic variation also needs to be kept in mind before analyzing the results.…”

Section: Discussionmentioning

confidence: 99%

“…Ziv-aflibercept is an intravenous formulation approved for the treatment of metastatic colorectal cancer[10] and there are few reports of the safety and efficacy of intravitreally administered off-label intravitreal ziv-aflibercept (IVZ) in patients with BRVO. [111213] IVZ is a similar molecule to IVA with a higher osmolarity in IVZ leading to concerns of intraocular toxicity. [14] A head-to-head comparison of IVA and IVB in treatment naïve BRVO cases with ME showed no significant differences in best corrected visual acuity (BCVA), central macular thickness (CMT), and mean number of injections at 12 months.…”

mentioning

confidence: 99%

“…[1617] Few reports have also shown the clinical outcomes of IVZ through 1 year. [1112] However, a comparison between IVB and IVZ has not been reported in the literature.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion

Braimah

Singh

Uplanchiwar

et al. 2019

Indian J Ophthalmol

Self Cite

View full text Add to dashboard Cite

Purpose: To compare the effectiveness of treatment with intravitreal bevacizumab (IVB) and ziv-aflibercept (IVZ) in patients with macular edema (ME) post-branch retinal vein occlusion (BRVO). Methods: Patients with treatment naïve ME post-BRVO were included retrospectively if they received either IVB (0.05 ml/1.25 mg) or IVZ (0.05 ml/1.25 mg) monotherapy with a follow up of 12 months. Results: Thirty-two and 17 eyes received IVB and IVZ, respectively. The mean improvement in best corrected visual acuity (BCVA) was 0.36 ± 0.3 logarithm of minimum angle of resolution (logMAR) in the IVB group and 0.27 ± 0.3 in the IVZ group ( P = 0.35). The mean change in central macular thickness was 178.9 ± 180.9 and 173.5 ± 344.4 μm in IVB and IVZ groups, respectively ( P = 0.94). The mean number of injections was higher in the IVB group (4.0 ± 1.8) compared with 1.82 ± 0.8 in the IVZ group ( P < 0.0001). The IVZ group had significantly fewer number of visits ( P < 0.0001) and longer maximum treatment-free intervals ( P = 0.0081). Conclusion: IVZ appears to be cost-effective with the similar visual outcome and less number of visits in comparison to IVB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

“…[1617] Few reports have also shown the clinical outcomes of IVZ through 1 year. [1112] However, a comparison between IVB and IVZ has not been reported in the literature.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion

Braimah

Singh

Uplanchiwar

et al. 2019

Indian J Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series

2021

View full text Add to dashboard Cite

Aim To evaluate the efficacy of ziv-aflibercept in Ghanaian patients with macular edema (ME) secondary to retinal vein occlusion (RVO). Methodology In this retrospective study, the medical records of patients with ME secondary to RVO who had been treated with intravitreal ziv-aflibercept (IVZ) (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis with a minimum follow-up of 6 months were retrieved and analyzed. The main outcome measures are mean change in best-corrected visual acuity (BCVA) and central subfield foveal thickness (CSFT) measured on optical coherence tomography from baseline to 12 months post-IVZ, and ocular and systemic safety. Results Forty-three eyes were included in this study. Their mean age was 62.8 ± 11.9 years, 67.4% had at least 12-month duration of follow-up, 50% had primary open-angle glaucoma and 38 (88.4%) eyes were treatment naive. There was significant improvement in mean BCVA in LogMAR at 1 month post-initiation of IVZ (0.8 ± 0.5 vs. 1.1 ± 0.6), and visual improvement was maintained up to 12 months (p < 0.001). Eyes with ME following BRVO had better mean BCVA at baseline and on subsequent visits compared to eyes with CRVO/HRVO (p = 0.01). There was significant reduction in mean CSFT up to 12 months post-IVZ injection compared to baseline (p < 0.001). Ocular complications observed were consistent with complications associated with RVO. Conclusion We have observed significant improvement in functional and anatomic outcomes 12 months post-initiation of IVZ. There is the need to confirm long-term efficacy and safety of IVZ in a large prospective study.

show abstract